REMINDER: Our user survey closes on Friday, please submit your responses here.
Could an NDA restrict there release? If I was purchasing a company, I’d want to see the results before committing and wouldn’t want results released as they could significantly increase the sp and purchase price. Probably wishful thinking. ACTIV2 results should be imminent as well.
Good find Myst1! Here is the extract:
Inhaled interferon is another option that he said is being looked at in a very large clinical trial because it showed some promise in a smaller clinical trial of about 100-200 people, along with a handful of other drugs that are being investigated into clinal trial.
Dr. Shafer did say that he was disappointed there would be more at-home therapies available right now, and was surprised at how quickly highly effective vaccines were made available compared to drugs to treat the virus. But he said we have been “extremely lucky” with the mRNA vaccines, considering how low the rate of serious side effects are.
At-home therapy is, however, approved for older and high-risk people, but Dr. Shafer recommends getting tested first and foremost if you think you have been exposed so that you can become eligible for treatment.
“For prophylaxis, I believe that any day now, there will be an emergency use authorization to still receive one or more of the monoclonal antibody formulations, but not yet,” he said, adding that there is an oral drug that we’ll “hear about any day now” manufactured by Merck, as well as an inhaled Interferon.
Posted by Xviolet in another tread. Studies in Israel reveal SA variant is infecting vaccinated people 8 times more that other variants. Bad news for the world as it suggests this pandemic is far from over. Not long now syners until our elusive RNS lands.
https://www.timesofisrael.com/real-world-israeli-data-shows-south-african-variant-better-at-bypassing-vaccine/
Great post Joey, this matches my understanding after all the panic discussions on the board last night. There are two massive benefits that the home trial should show, firstly that they will add to our safety data and secondly that the drug can be administered at home.
Apologies if already shared. Tom Wilkinson tweeted about his new paper earlier and it looks very promising for SNG. It covers the number of global hospitalisations for respiratory based virus per year and the various treatment options. After reading this, I wouldn’t be surprised if we have a new trial for flu after the COVID train has got a bit further along.
https://journals.sagepub.com/doi/10.1177/1753466621995050
Can anyone translate the attached image?
https://twitter.com/nathanpsmad/status/1376972918928859149?s=21
From the comments it really does look like a bit of a homebrew project which would never get approval so no risk to us or our patent.
Which part GK? This: “These data confirm that the B.1, B.1.1.7 and 117 B.1.351 isolates have evolved to resist the IFN-I and IFN-III response.” I see this as a positive. By resist I assume they mean suppress? Surly if something is suppressed, adding more if it should help?
Activ2 progression to P3 and home trial results could land any time now. Global P3 seems to be taking a little longer than most would have liked but it’s progressing all the same. I think you have picked a good time to join. Should hopefully get some results in the next 2 weeks.
Interesting distraction from the LSE SNG daily soap opera:
https://www.biorxiv.org/content/10.1101/2021.03.20.436257v1.full.pdf
This is a pre print which will be published soon.
From my limited understanding they are basically saying the virus is excellent at mutating and will get better at becoming vaccine immune and at suppressing interferons. Ifn B seems to be the golden ticket along with one other interferon tested.
“ The emergence of SARS-CoV-2 variants with enhanced transmissibility, pathogenesis and resistance to vaccines presents urgent challenges for curbing the COVID-19 pandemic.
While Spike mutations that enhance virus infectivity may drive the emergence of these novel variants, studies documenting a critical a role for interferon responses in the early control of SARS-CoV-2 infection, combined with the presence of viral genes that limit these responses, suggest that interferons may also influence SARS-CoV-2 evolution. Here, we compared the potency of 17 different human interferons against 5 viral lineages sampled during the course of the global outbreak that included ancestral and emerging variants. Our data revealed increased interferon resistance in emerging SARS-CoV-2 variants, indicating that evasion of innate immunity is a significant driving force for SARS-CoV-2 evolution. These findings have implications for the increased lethality of emerging variants and highlight the interferon subtypes that may be most successful in the treatment of early infections.”
We need a tamiflu for COVID that keeps people out of hospital. Hmmm maybe they should check the p2 results of their Activ2 trail. Sadly I couldn’t find any mention of sng except for in the slides. We’re we mentioned? Thanks for sharing Ducati2!
Morning all,
As we all wait patiently for the next elusive RNS I thought I’d share some timeline notes a made back in January:
Multi bag time lines 29th jan
Activ 2 US started 10 Feb-
Progress to p3 start 17 March or EUA
Home trial results- 20-25 March
Last dosing P3 - 6 weeks from start - 24-30 Feb
P3 RNS read out- 23-28th April
US EUA - next seven weeks
Pre orders,Take over bid, Licensing deals - could land any day.
So as you can see I was miles off with the P3 last dosing as i underestimated how doing this globally would slow things down. However the rest are still in scope and we should have some significant news dropping any day now. Good luck all
AstraZeneca PLC - US supply agreement for additional AZD7442 doses #AZN @AstraZeneca https://www.**********.co.uk/rns/announcement/9a1ab20e-9a27-4b64-b20d-a5446e065919
This might be the sign of things to come for SNG!